SPPI News and Press, Spectrum Pharmaceuticals Inc. From 06/16/20

Spectrum Pharmaceuticals, Inc. (NASDAQ-GS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced a poster presentation of the results for preclinical studies evaluating the administration of ROLONTIS on the same day as chemotherapy in a rodent mo...

Spectrum Pharmaceuticals, Inc. (NASDAQ-GS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced that Lyndah K. Dreiling, M.D., MBA, has been named Senior Vice President, Clinical Development. “We are excited to welcome Dr. Lyndah Drei...

Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, announced today that management will present an overview of the company's business strategy and development-stage programs at the Jefferies Virtual Healthcare Conference 20...

Image source: The Motley Fool. Spectrum Pharmaceuticals Inc   (NASDAQ: SPPI) Q1 2020 Earnings Call May 8, 2020 , 11:30 p.m. ET Operator Continue reading

Spectrum Pharmaceuticals, Inc. (SPPI) Q1 2020 Earnings Conference Call May 7, 2020 16:30 ET Company Participants Robert Uhl - Westwicke ICR Joseph Turgeon - President & CEO Kurt Gustafson - CFO Francois Lebel - Chief Medical Officer Thomas Riga - COO Conference Call Pa...

Spectrum Pharmaceuticals (NASDAQ: SPPI ): Q1 Non-GAAP EPS of -$0.22 beats by $0.05 ; GAAP EPS of -$0.36 misses by $0.01 . More news on: Spectrum Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

BLA for ROLONTIS ® (eflapegrastim) under active FDA review - PDUFA date on October 24, 2020 ROLONTIS same day dosing study initiated Updated Poziotinib strategy implemented to include new dosing regimens Poziotinib ZENITH20 Cohort 3 fully enrolled Management to ...

Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced it will host a conference call to discuss the first quarter 2020 financial results and provide a corporate update on Thursday, May 7, 2020 at 4:30 p.m. East...

Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced dosing of the first patient in a clinical trial to evaluate the administration of ROLONTIS on the same day as chemotherapy. The trial will evaluate the du...

ZENITH20 Phase 2 clinical trial amended to include new dosing regimens aimed at improving therapeutic index Management to host webcast and conference call today to review data and program strategy at 8:30 a.m. ET Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical compa...